keyword
MENU ▼
Read by QxMD icon Read
search

Cancer pain, neuropathy, pain

keyword
https://www.readbyqxmd.com/read/29781509/comparative-analgesic-efficacy-of-pregabalin-administered-according-to-either-a-prevention-protocol-or-an-intervention-protocol-in-rats-with-cisplatin-induced-peripheral-neuropathy
#1
F Y Han, A Kuo, J R Nicholson, L Corradinni, M T Smith
Chemotherapy-induced peripheral neuropathy (CIPN) is a type of peripheral neuropathic pain that may be dose-limiting in patients administered potentially curative cancer chemotherapy dosing regimens. In cancer survivors, persistent CIPN adversely affects patient quality of life and so adjuvant drugs (anticonvulsants e.g. pregabalin or antidepressants e.g. amitriptyline) are recommended for the relief of CIPN. However, most studies in rodent models of CIPN involve administration of single bolus doses of adjuvant drugs to assess pain-relieving efficacy...
May 21, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29781075/effectiveness-of-gabapentin-pharmacotherapy-in-chemotherapy-induced-peripheral-neuropathy
#2
Magdalena Magnowska, Natalia Iżycka, Joanna Kapoła-Czyż, Anna Romała, Jakub Lorek, Marek Spaczyński, Ewa Nowak-Markwitz
OBJECTIVES: Chemotherapy-induced peripheral neuropathy (CIPN) is a common chemotherapy side effect, but its prevention and treatment remains a challenge. Neurotoxicity may lead to dose limitation or even treatment discontinuation, and therefore potentially affect the efficacy of anticancer treatment and long term outcomes. The practice to administer gabapentin for neuropathy may be applicable, but is limited by insufficient studies. The aim of our study was to assess the presence of chemotherapy-induced peripheral neuropathy in ovarian cancer patients treated with first-line paclitaxel and carboplatin chemotherapy and evaluate the effectiveness of gabapentin in treatment of this condition...
2018: Ginekologia Polska
https://www.readbyqxmd.com/read/29735874/-effectiveness-of-non-pharmacologic-interventions-in-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#3
REVIEW
Pok Ja Oh, You Lim Kim
PURPOSE: This study was conducted to evaluate the effectiveness of non-pharmacologic interventions in chemotherapy-induced peripheral neuropathy (CIPN). METHODS: PubMed, Cochrane Library CENTRAL, EMBASE, CINAHL, and several Korean databases (Until August 2017) were searched. The main search strategy combined terms for peripheral neuropathy and presence of neoplasms. The risk of bias was assessed using the Cochrane's Risk of Bias tool for randomized studies and the Risk of Bias Assessment tool for non-randomized studies...
April 2018: Journal of Korean Academy of Nursing
https://www.readbyqxmd.com/read/29729786/oncology-acupuncture-for-chronic-pain-in-cancer-survivors-a-reflection-on-the-american-society-of-clinical-oncology-chronic-pain-guideline
#4
REVIEW
Weidong Lu, David S Rosenthal
Chronic pain syndromes associated with cancer treatment are common but difficult to manage. The American Society of Clinical Oncology recently published a practice guideline to address the unmet needs of cancer survivors, Management of Chronic Pain in Survivors of Adult Cancers, which stresses the importance of implementing integrative therapies including acupuncture. This review focuses on randomized clinical trials of acupuncture for chronic pain in cancer survivors, including its use in chemotherapy-induced peripheral neuropathy, aromatase inhibitor-associated arthralgia, and post neck dissection pain, and provides future directions of oncology acupuncture research in cancer survivorship...
June 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29705914/a-longitudinal-study-of-painless-and-painful-intercostobrachial-neuropathy-after-breast-cancer-surgery
#5
S La Cesa, P Sammartino, C Mollica, G Cascialli, G Cruccu, A Truini, M Framarino-Dei-Malatesta
Intercostobrachial neuropathy, often resulting in neuropathic pain, is a common complication of breast cancer surgery. In this 1-year longitudinal study, we aimed at seeking information on the frequency, clinical features, and course of painless and painful intercostobrachial neuropathy. We enrolled 40 women previously undergoing breast cancer surgery. In these patients, we collected, at 3, 6 and 12 months after surgery, clinical and quantitative sensory testing (QST) variables to diagnose intercostobrachial neuropathy, DN4 questionnaire to identify neuropathic pain, Neuropathic Pain Symptom Inventory to assess the different neuropathic pain symptoms, the Beck Depression Inventory to assess depressive symptoms, and SF36 to assess quality of life and Patient Global Impression of Change...
April 29, 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29695418/role-of-complement-in-a-rat-model-of-paclitaxel-induced-peripheral-neuropathy
#6
Jijun Xu, Lingjun Zhang, Mian Xie, Yan Li, Ping Huang, Thomas L Saunders, David A Fox, Richard Rosenquist, Feng Lin
Chemotherapy-induced peripheral neuropathy (CIPN) is a painful and debilitating side effect of cancer chemotherapy with an unclear pathogenesis. Consequently, the available therapies for this neuropathic pain syndrome are inadequate, leading to a significantly reduced quality of life in many patients. Complement, a key component of the innate immune system, has been associated with neuroinflammation, a potentially important trigger of some types of neuropathic pain. However, the role of complement in CIPN remains unclear...
April 25, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29681015/cold-therapy-to-prevent-paclitaxel-induced-peripheral-neuropathy
#7
Claire Griffiths, Nancy Kwon, Jennifer L Beaumont, Judith A Paice
PURPOSE: This case-control study was designed to assess the efficacy of cryotherapy to prevent paclitaxel-induced painful peripheral neuropathy in women with breast cancer. METHODS: Participants served as their own paired control, with randomization of the cooled glove/sock to either the dominant or the non-dominant hand/foot, worn for 15 min prior to, during, and 15 min after completion of the paclitaxel infusion. Outcome measures included the Neuropathic Pain Symptom Inventory, the Brief Pain Inventory, and quantitative sensory testing...
April 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29671505/care-of-the-colorectal-cancer-survivor
#8
Kristina Burgers, Clint Moore, Lori Bednash
Colorectal cancer is the fourth most common cancer in the United States and has a five-year survival rate of 65%. The American Cancer Society and other experts have released guidelines on surveillance, health promotion, screening for other malignancies, and management of treatment effects. Surveillance for disease recurrence should occur every three to six months for the first two to three years, then every six months for a total of five years. Each visit should include a history and physical examination, routine care for chronic medical conditions, and screening for other primary cancers according to guidelines for the general population...
March 1, 2018: American Family Physician
https://www.readbyqxmd.com/read/29660270/protective-effect-of-a-mitochondria-targeted-peptide-against-the-development-of-chemotherapy-induced-peripheral-neuropathy-in-mice
#9
Satoshi Toyama, Naohito Shimoyama, Hazel H Szeto, Peter W Schiller, Megumi Shimoyama
Several chemotherapeutic agents used for cancer treatment induce dose-limiting peripheral neuropathy that compromises patients' quality of life and limits cancer treatment. Recently, mitochondrial dysfunction has been shown to be involved in the mechanism of chemotherapy-induced peripheral neuropathy. SS-20 is a mitochondria-targeted peptide that promotes mitochondrial respiration and restores mitochondrial bioenergetics. In the present study, we examined the protective effect of SS-20 against the development of chemotherapy-induced peripheral neuropathy utilizing a murine model of peripheral neuropathy induced by oxaliplatin, a first-line chemotherapy agent for colon cancer...
April 18, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29623757/icariin-a-flavonoid-with-anti-cancer-effects-alleviated-paclitaxel-induced-neuropathic-pain-in-a-sirt1-dependent-manner
#10
Yulong Gui, Jie Zhang, Liang Chen, Shunyuan Duan, Jing Tang, Wei Xu, Aiyuan Li
Background One of the most common side effects of paclitaxel was dosage-dependently painful neuropathy. Various reports indicated that spinal neuroinflammation was involved in paclitaxel-induced neuropathic pain. This study investigated the effect of icariin on paclitaxel-induced neuroinflammation and peripheral neuropathy in rats. Methods Two parts were included in this study. In part one, the effect of icariin on paclitaxel-induced neuropathic pain was investigated. Mechanical thresholds were measured as primary outcomes...
January 2018: Molecular Pain
https://www.readbyqxmd.com/read/29622698/value-of-supportive-care-pharmacogenomics-in-oncology-practice
#11
REVIEW
Jai N Patel, Lauren A Wiebe, Henry M Dunnenberger, Howard L McLeod
Genomic medicine provides opportunities to personalize cancer therapy for an individual patient. Although novel targeted therapies prolong survival, most patients with cancer continue to suffer from burdensome symptoms including pain, depression, neuropathy, nausea and vomiting, and infections, which significantly impair quality of life. Suboptimal management of these symptoms can negatively affect response to cancer treatment and overall prognosis. The effect of genetic variation on drug response-otherwise known as pharmacogenomics-is well documented and directly influences an individual patient's response to antiemetics, opioids, neuromodulators, antidepressants, antifungals, and more...
April 5, 2018: Oncologist
https://www.readbyqxmd.com/read/29617189/cumulative-burden-of-morbidity-among-testicular-cancer-survivors-after-standard-cisplatin-based-chemotherapy-a-multi-institutional-study
#12
Sarah L Kerns, Chunkit Fung, Patrick O Monahan, Shirin Ardeshir-Rouhani-Fard, Mohammad I Abu Zaid, AnnaLynn M Williams, Timothy E Stump, Howard D Sesso, Darren R Feldman, Robert J Hamilton, David J Vaughn, Clair Beard, Robert A Huddart, Jeri Kim, Christian Kollmannsberger, Deepak M Sahasrabudhe, Ryan Cook, Sophie D Fossa, Lawrence H Einhorn, Lois B Travis
Purpose In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs). Patients and Methods Participants were ≤ 55 years of age at diagnosis, finished first-line chemotherapy ≥ 1 year previously, completed a comprehensive questionnaire, and underwent physical examination. Treatment data were abstracted from medical records. A CBM score encompassed the number and severity of AHOs, with ordinal logistic regression used to assess associations with exposures...
April 4, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29587605/chondritis-of-the-ear-after-docetaxel-carboplatin-chemotherapy
#13
Tae Hoon Kong, Sung Min Han, Young Joon Seo
Docetaxel, derived from the yew tree, belongs to the taxane family of medications. It works by disrupting the normal function of microtubules, thereby stopping cell division. Docetaxel is used in the treatment of ovarian, breast, esophageal, gastric, prostate, lung, and head and neck cancers. Common side effects include hair loss, low blood cell counts, peripheral neuropathy, vomiting, and muscle pain. Auricular chondritis with ear deformity has not been reported previously as a side effect of docetaxel. In this paper, we present the case of a 64-year-old male patient with chondritis accompanied by ear deformity that developed due to docetaxel-carboplatin chemotherapy for non-small cell lung cancer...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29565955/chronic-pelvic-pain-neurogenic-or-non-neurogenic-warm-detection-threshold-testing-supports-a-diagnosis-of-pudendal-neuropathy
#14
Stanley J Antolak, Christopher M Antolak
BACKGROUND: Chronic pelvic pain (CPP) in men is rarely considered to have a neurogenic (neuropathic) basis. Separation of neurogenic from non-neurogenic pain is possible using clinical examination and neurophysiologic tests. A definite diagnosis of neuropathic pain can be made. OBJECTIVES: We aim to demonstrate that definite pudendal neuropathic abnormalities can be supported by a quantitative sensory test (QST) called the warm temperature threshold detection (WDT) test in men with CPP...
March 2018: Pain Physician
https://www.readbyqxmd.com/read/29540562/monoacylglycerol-lipase-inhibitors-reverse-paclitaxel-induced-nociceptive-behavior-and-proinflammatory-markers-in-a-mouse-model-of-chemotherapy-induced-neuropathy
#15
Zachary Curry, Jenny Wilkerson, Deniz Bagdas, Sarah Kyte, Nipa Patel, Giulia Donvito, Mohammed A Mustafa, Justin Poklis, Micah Niphakis, Ku-Lung Hsu, Benjamin F Cravatt, David A Gewirtz, M Imad Damaj, Aron H Lichtman
Although paclitaxel effectively treats various cancers, its debilitating peripheral neuropathic pain side effects often persist long after treatment has ended. Therefore, a compelling need exists for the identification of novel pharmacologic strategies to mitigate this condition. As inhibitors of monoacylglycerol lipase (MAGL), the primary hydrolytic enzyme of the endogenous cannabinoid 2-arachidonyolglycerol, produce antinociceptive effects in numerous rodent models of pain, we investigated whether inhibitors of this enzyme (i...
March 14, 2018: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29524582/associations-between-perceived-stress-and-chemotherapy-induced-peripheral-neuropathy-and-otoxicity-in-adult-cancer-survivors
#16
Christine Miaskowski, Steven M Paul, Judy Mastick, Gary Abrams, Kimberly Topp, Betty Smoot, Kord M Kober, Margaret Chesney, Melissa Mazor, Grace Mausisa, Mark Schumacher, Yvette P Conley, Jennifer Henderson Sabes, Steven Cheung, Margaret Wallhagen, Jon D Levine
CONTEXT: The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. OBJECTIVES: In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds...
March 7, 2018: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29503217/estimating-the-frequency-severity-and-clustering-of-spade-symptoms-in-chronic-painful-chemotherapy-induced-peripheral-neuropathy
#17
Robert Knoerl, Zach Chornoby, Ellen M L Smith
Patients undergoing treatment for cancer commonly experience symptoms such as sleep disturbance, pain, anxiety, depression, and low energy/fatigue (SPADE), subsequently altering physical function and complicating effective symptom management. However, little is known about the frequency, severity, and clustering of SPADE symptoms in individuals with chronic painful chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this cross-sectional, secondary analysis was to describe the frequency, severity, and clustering of SPADE symptoms and their association with physical function in individuals with chronic painful CIPN...
March 1, 2018: Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses
https://www.readbyqxmd.com/read/29462248/quality-of-life-analysis-of-the-mito-8-mango-bgog-ov1-ago-ovar2-16-engot-ov1-gcig-study-comparing-platinum-based-versus-non-platinum-based-chemotherapy-in-patients-with-partially-platinum-sensitive-recurrent-ovarian-cancer
#18
M C Piccirillo, G Scambia, A Bologna, S Signoriello, I Vergote, K Baumann, D Lorusso, V Murgia, R Sorio, G Ferrandina, C Sacco, G Cormio, E Breda, S Cinieri, D Natale, G Mangili, C Pisano, S C Cecere, M Di Napoli, V Salutari, F Raspagliesi, L Arenare, A Bergamini, J Bryce, G Daniele, C Gallo, S Pignata, F Perrone
Background: MITO-8 showed that prolonging platinum-free interval by introducing non-platinum-based chemotherapy (NPBC) does not improve prognosis of patients with partially platinum-sensitive recurrent ovarian cancer. Quality of life (QOL) was a secondary outcome. Patients and methods: Ovarian cancer patients recurring or progressing 6-12 months after previous platinum-based chemotherapy (PBC) were randomized to receive PBC or NPBC as first treatment. QOL was assessed at baseline, 3rd and 6th cycle, with the EORTC C-30 and OV-28 questionnaires...
February 16, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29461625/beyond-symptomatic-relief-for-chemotherapy-induced-peripheral-neuropathy-targeting-the-source
#19
REVIEW
Jiacheng Ma, Annemieke Kavelaars, Patrick M Dougherty, Cobi J Heijnen
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse side effect of many chemotherapeutic agents, affecting >60% of patients with cancer. Moreover, CIPN persists long into survivorship in approximately 20% to 30% of these patients. To the authors' knowledge, no drugs have been approved to date by the US Food and Drug Administration to effectively manage chemotherapy-induced neuropathic pain. The majority of the drugs tested for the management of CIPN aim at symptom relief, including pain and paresthesia, yet are not very efficacious...
February 20, 2018: Cancer
https://www.readbyqxmd.com/read/29445301/comparative-effectiveness-of-early-line-nab-paclitaxel-vs-paclitaxel-in-patients-with-metastatic-breast-cancer-a-us-community-based-real-world-analysis
#20
Reshma L Mahtani, Monika Parisi, Stefan Glück, Quanhong Ni, Siyeon Park, Corey Pelletier, Claudio Faria, Fadi Braiteh
Background: Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness of nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer using data from an electronic medical record database from community practices across the USA. Methods: We performed a retrospective cohort study using fully de-identified data from an independent US electronic medical record platform of patients with metastatic breast cancer initiating single-agent nab -paclitaxel or paclitaxel as a first- or second-line treatment from December 1, 2010 to October 6, 2014...
2018: Cancer Management and Research
keyword
keyword
76402
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"